Literature DB >> 19738477

The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre.

Ioannis P Giannousis1, George V Papatheodoridis, Melanie J Deutsch, Spilios G Manolakopoulos, Emanuel K Manesis, John S Koskinas, Athanasios J Archimandritis.   

Abstract

OBJECTIVE: To investigate the burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre.
METHODS: We evaluated the main epidemiological characteristics of 1080 consecutive adult patients, seen at our outpatient liver clinic between 2002 and 2007, with chronic hepatitis B (HBV) and/or C (HCV) virus infection, alcoholic liver disease (ALD) or nonalcoholic fatty liver disease (NAFLD). Our patient population was divided into two groups in relation to the time of the first visit (period A: 2002-2004, period B: 2005-2007).
RESULTS: Among our patient population, 86.1% had chronic HBV and/or HCV infection (chronic HCV alone: 44.9%), 9.2% NAFLD and 4.8% ALD. From period A to B, there was a decrease in chronic HBV cases (44.0 vs. 37.8%, P = 0.045) with immigrants being responsible for 35.5% of them and being more frequent in period B than A (39.7 vs. 30.5%, P = 0.046). In chronic hepatitis B, hepatitis B e antigen-positive patients, who were more frequent immigrants compared with hepatitis B e antigen-negative patients (65.5 vs. 29.5%, P = 0.001), increased from period A to B (8.0 vs. 17.6%, P = 0.045). Intravenous drug use was reported by 41.2% of HCV patients with its proportion increasing from period A to B (32.5 vs. 47.4%, P = 0.002). Decompensated cirrhosis was present in 67, 10, 11 and 3% of patients with ALD, HBV, HCV and NAFLD, respectively.
CONCLUSION: At Greek tertiary centres, chronic viral hepatitis remains responsible for most chronic liver disease cases, but its epidemiology is changing owing to immigrants and intravenous drug users.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19738477     DOI: 10.1097/MEG.0b013e328331115b

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Clinical outcomes of compensated and decompensated cirrhosis: A long term study.

Authors:  Dimitrios N Samonakis; Mairi Koulentaki; Constantina Coucoutsi; Aikaterini Augoustaki; Chryssavgi Baritaki; Emmanuel Digenakis; Nikolaos Papiamonis; Maria Fragaki; Erminia Matrella; Maria Tzardi; Elias A Kouroumalis
Journal:  World J Hepatol       Date:  2014-07-27

2.  Short-term clinical outcomes of patients admitted with chronic liver disease to selected teaching hospitals in Ethiopia.

Authors:  Behailu Terefe Tesfaye; Esayas Kebede Gudina; Dula Dessalegn Bosho; Teshale Ayele Mega
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

3.  Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting.

Authors:  Kanellos Rafail Koustenis; Olga Anagnostou; Hariklia Kranidioti; Sofia Vasileiadi; Pinelopi Antonakaki; Evangelia Koutli; Paris Pantsas; Melanie Deutsch; Spilios Manolakopoulos
Journal:  Ann Gastroenterol       Date:  2020-01-20

4.  The changing epidemiology of hepatocellular carcinoma in Greece.

Authors:  George E Markakis; Andreas Koulouris; Maria Tampaki; Evangelos Cholongitas; Melanie Deutsch; George V Papatheodoridis; John Koskinas
Journal:  Ann Gastroenterol       Date:  2021-12-06

Review 5.  Epidemiology of hepatitis C in Greece.

Authors:  Christos Triantos; Christos Konstantakis; Paraskeui Tselekouni; Maria Kalafateli; Ioanna Aggeletopoulou; Spilios Manolakopoulos
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

6.  Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.

Authors:  Mingjuan Tan; Ajeet S Bhadoria; Fuqiang Cui; Alex Tan; Judith Van Holten; Philippa Easterbrook; Nathan Ford; Qin Han; Ying Lu; Marc Bulterys; Yvan Hutin
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.